

Clinical Flowchart for Cancer Immunotherapy

(Ver1.1 1 Oct 2019)

Flowchart

The flow chart describes the process of the Cancer Immunotherapy (CAR-T, DC, CIK, DC-CIK) to patients, from the initial selection of patients, through production of the cells for the immunotherapy, to post-treatment monitoring and efficacy assessment.

#	Step	Responsibility
1	Identify suitable patients for Cancer Immunotherapy (CPI, CAR-T, ALLO-T, TCR-T, TAA-T, DC, CIK, DC-CIK)	Self-referral, Agent, or a medical doctor
2	Potential patients receive information regarding the treatment	Direct communion, Agent, or a medical doctor
3	Refer patient to Oncologist for baseline assessment	Agent, Vamos, or a medical doctor
4	Medical screening by in-house physician	Partner Hospital
5	Assess patient's baseline clinical status to determine eligibility (see Protocol for details)	Partner Oncologist
6	Conduct specific lab tests to determine eligibility (see Protocol for details)	Partner Oncologist
7	MAKE A DECISION, sign the sales contract	Partner Oncologist / Hospital
8	Obtain patient's consent & if applicable, institutional ethics approval for compassionate use	Partner Oncologist / Hospital
9	Schedule an Apheresis (if applicable)	Partner Hospital
10	Conduct Apheresis (if applicable)	Partner Hospital
11	Local laboratory conducts PBMC isolation, cryo-preservation & ship to the manufacturer (Vamos)	Manufacturer's coordinator & Apheresis Unit
12	Pre-treatment	Partner Oncologist / Hospital
13	Immunotherapy (infusion)	Partner Oncologist / Hospital
14	Post-injection combination treatment (if applicable)	Partner Oncologist / Hospital
15	Post-treatment - patient monitoring, managing possible adverse effects (if any) (see the Protocol for details)	Partner Oncologist / Hospital
16	End of treatment – Imaging (CT/MRI/ PET-CT) or Biopsy (month 3 and 6 after the first dose) for Efficacy assessment	Partner Oncologist / Hospital